An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 ...

The phase 3 trials are - Plozasiran (ARO-APOC3) in Severe Hypertriglyceridemia and Familial Chylomicronemia Syndrome, Olpasiran, licensed to Amgen and targeting Cardiovascular Disease, and ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to ...

T he RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

2. Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE The “head-scratching” findings put more pressure on the eagerly awaited outcomes studies, says Karol Watson. 3. Aortic Stenosis ...

Concrete, steel and wood are some of the most common choices to compose the structure of stairs due to their high strength and versatility. But, when combined, these different materials expand ...

Cholesterol synthesis and gallstone formation are promoted by trimethylamine-N-oxide (TMAO), a derivative of trimethylamine, which is a metabolite of gut microbiota. However, the underlying ...

A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) and ...

Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors.

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Upcoming patent losses are looming large for a number of ...

AHA 2024 New Pill Successfully Lowers Lp(a) Levels Muvalaplin shows promise in lowering lipoprotein(a) levels, which are genetically determined and confer cardiovascular risk and for which no ...

Amgen has reported encouraging mid-stage results for its olpasiran candidate for reducing lipoprotein(a) – a risk factor for atherosclerotic cardiovascular disease – and now plans to move ...